The Gut in Ankylosing Spondylitis and Other Spondyloarthropathies: Inflammation Beneath the Surface

Journal of Rheumatology

Volumn 30, Issue 11, 2003, Pages 2306-2307

  De Keyser, Filip ^a   Mielants, Herman ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAEBETA7 INTEGRIN; CD163 ANTIGEN; ETANERCEPT; HLA B27 ANTIGEN; IMMUNOMODULATING AGENT; INFLIXIMAB; INTEGRIN; NITRIC OXIDE SYNTHASE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTAGONIST; UNCLASSIFIED DRUG; UVOMORULIN;

ANKYLOSING SPONDYLITIS; CELL ADHESION; CELL LINEAGE; CHRONIC INFLAMMATION; COLONOSCOPY; CROHN DISEASE; EDITORIAL; ENDOSCOPY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTESTINE METAPLASIA; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; RISK FACTOR; SPONDYLOARTHROPATHY; T LYMPHOCYTE;

ENTERITIS; HUMANS; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING;

EID: 0242693174     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (13)

1. De Keyser F, Elewaut D, De Vos M, et al. Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am 1998;24:785-813.
2. Cuvelier C, Barbatis C, Mielants H, et al. Histopathology of intestinal inflammation related to reactive arthritis. Gut 1987;28:394-401.
3. Van Damme N, Elewaut D, Baeten D, et al. Gut mucosal T cell lines from ankylosing spondylitis patients are enriched with alpha E beta 7 integrin. Clin Exp Rheumatol 2001;19:681-7.
4. Demetter P, De Vos M, Van Damme N, et al. Focal upregulation of E-cadherin-catenin complex in inflamed bowel mucosa but reduced expression in ulcer-associated lineage. Am J Clin Pathol 2000;114:364-70.
5. Demetter P, Baeten D, De Keyser F, et al. Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex. Ann Rheum Dis 2000;59:211-6.
6. Baeten D, Demetter P, Cuvelier C, et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol 2002;196:343-50.
7. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001;96:730-4.
8. Hoffman IE, Demetter P, Peeters M, et al. Anti-Saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis 2003;62:455-9.
9. Lamarque D, Tran Van Nhieu J, Bernardeau C, et al. Lymphocytic infiltration and expression of inducible nitric oxide synthase in human duodenal and colonic mucosa is a characteristic feature of ankylosing spondylitis. J Rheumatol 2003;30:2428-36.
10. De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996;110:1696-703.
11. Mielants H, Veys EM, Cuvelier C, et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 1995;22:2273-8.
12. Baeten D, De Keyser F, Mielants H, Veys EM. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2002;16:537-49.
13. De Keyser F, Baeten D, Van den Bosch F, Kruithof E, Mielants H, Veys E. Infliximab in patients with spondyloarthropathy: clinical efficacy, safety and biological immunomodulation. Rheum Dis Clin North Am 2003;29:463-79.